Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 10 04:00PM ET
20.65
Dollar change
+0.60
Percentage change
2.99
%
Index- P/E- EPS (ttm)-1.05 Insider Own90.19% Shs Outstand352.08M Perf Week4.98%
Market Cap7.27B Forward P/E24.65 EPS next Y0.84 Insider Trans0.01% Shs Float34.55M Perf Month3.25%
Income-368.00M PEG- EPS next Q0.24 Inst Own9.50% Short Float3.11% Perf Quarter30.53%
Sales4.68B P/S1.55 EPS this Y-18.73% Inst Trans-8.77% Short Ratio1.64 Perf Half Y38.03%
Book/sh18.71 P/B1.10 EPS next Y41.22% ROA-2.77% Short Interest1.08M Perf Year31.86%
Cash/sh0.99 P/C20.78 EPS next 5Y13.00% ROE-5.49% 52W Range13.16 - 21.69 Perf YTD21.04%
Dividend Est.- P/FCF- EPS past 5Y- ROI-3.29% 52W High-4.79% Beta0.42
Dividend TTM- Quick Ratio0.95 Sales past 5Y2.77% Gross Margin54.48% 52W Low56.91% ATR (14)0.50
Dividend Ex-Date- Current Ratio1.57 EPS Y/Y TTM-77.31% Oper. Margin4.04% RSI (14)62.80 Volatility2.39% 2.40%
Employees13300 Debt/Eq0.70 Sales Y/Y TTM18.01% Profit Margin-7.86% Recom2.19 Target Price21.75
Option/ShortYes / Yes LT Debt/Eq0.70 EPS Q/Q104.72% Payout- Rel Volume1.35 Prev Close20.05
Sales Surprise1.96% EPS Surprise8.07% Sales Q/Q18.77% EarningsOct 30 BMO Avg Volume656.90K Price20.65
SMA204.45% SMA503.83% SMA20022.35% Trades Volume911,789 Change2.99%
Date Action Analyst Rating Change Price Target Change
TodayDowngrade Citigroup Buy → Neutral $24 → $22
Dec-02-24Downgrade Morgan Stanley Overweight → Equal-Weight $19
Oct-15-24Upgrade Evercore ISI In-line → Outperform $19 → $25
Jul-10-24Initiated Raymond James Outperform $19
May-06-24Upgrade Morgan Stanley Equal-Weight → Overweight $16 → $18
Jan-04-24Downgrade Evercore ISI Outperform → In-line $19 → $17
Dec-12-23Initiated Stifel Hold $16
Oct-03-23Resumed Evercore ISI Outperform $20
May-30-23Resumed Morgan Stanley Equal-Weight $20
Mar-09-23Initiated Needham Hold
Today 06:59AM
Nov-22-24 02:31PM
02:31PM
Nov-14-24 07:00AM
Oct-31-24 03:06AM
05:52PM Loading…
Oct-30-24 05:52PM
07:00AM
Oct-29-24 09:05AM
Oct-23-24 09:45AM
Oct-14-24 11:38AM
10:57AM
07:00AM
Oct-09-24 08:00AM
Oct-02-24 08:40AM
Oct-01-24 07:00AM
11:01AM Loading…
Sep-18-24 11:01AM
Sep-16-24 06:35PM
12:26PM
09:52AM
07:22AM
Aug-07-24 11:37PM
Aug-05-24 06:45PM
Aug-01-24 10:41AM
Jul-31-24 03:55PM
12:08PM
07:00AM
Jul-30-24 06:33PM
Jul-25-24 06:33PM
Jul-24-24 06:24PM
Jul-17-24 06:53PM
12:05PM Loading…
Jul-11-24 12:05PM
Jul-08-24 07:00AM
Jun-17-24 07:00AM
Jun-10-24 07:00AM
Jun-03-24 07:00AM
May-29-24 04:30PM
May-28-24 09:00AM
06:59AM
May-03-24 04:06PM
03:35PM
May-02-24 03:03PM
May-01-24 11:54AM
08:33AM
06:58AM
Apr-29-24 07:00AM
Apr-25-24 08:30AM
Apr-24-24 10:01AM
Apr-18-24 07:00AM
Apr-15-24 12:00PM
Mar-27-24 07:00AM
Mar-25-24 12:00PM
Mar-20-24 12:20PM
Mar-19-24 08:50AM
Mar-08-24 10:10AM
Feb-28-24 08:00AM
Feb-23-24 03:05PM
Feb-22-24 11:30AM
Feb-21-24 10:35PM
07:04PM
09:30AM
07:36AM
07:31AM
07:00AM
06:58AM
Feb-15-24 09:15AM
Feb-14-24 12:10PM
10:00AM
Feb-05-24 12:00PM
Jan-17-24 06:54PM
Jan-09-24 12:41PM
Jan-08-24 06:59AM
Jan-03-24 09:00AM
Nov-28-23 01:25PM
Nov-15-23 06:59AM
Nov-03-23 11:01AM
Nov-01-23 03:19PM
09:21AM
06:58AM
Oct-26-23 06:59AM
Oct-16-23 12:00PM
Oct-04-23 06:59AM
Sep-29-23 10:15AM
10:00AM
Sep-26-23 06:59AM
Sep-20-23 06:59AM
Sep-19-23 08:32AM
Sep-18-23 11:56AM
Sep-14-23 05:25PM
Sep-12-23 06:59AM
Sep-11-23 08:00AM
07:07AM
Sep-06-23 05:58PM
06:59AM
Aug-29-23 07:00AM
Aug-24-23 07:00AM
Aug-02-23 05:25PM
06:59AM
Aug-01-23 08:00AM
Jul-11-23 07:00AM
Jul-06-23 07:00AM
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SAUNDERS BRENT LCEO and Chairman of the BoardAug 05 '24Buy15.6632,250505,067595,169Aug 07 05:29 PM